5 Healthcare Stocks Moving the Market

March 5, 2019 -- InvestorsHub NewsWire -- Microcap Speculators -- Below are several healthcare stocks making significant strides in the healthcare market.

One sector that is forecasted to grow is the global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the period of 2017-2022. One technology we think will lead the way in this growth are non-invasive therapies. One non-invasive developer we like is Endonovo Therapeutics, Inc. (USOTC: ENDV). The company has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company’s already rapid growth. Do your due diligence on ENDV.

We are highlighting: Endonovo Therapeutics, Inc. (USOTC: ENDV), Aphria, Inc. (NYSE: APHA), Avinger, Inc. (NASDAQ: AVGR), BioPharmX Corporation (BPMX), and Valeritas Holdings, Inc. (NASDAQ: VLRX).

Endonovo Therapeutics, Inc. (USOTC: ENDV) (Market Cap: $9.838M, Share Price: $0.0201), a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy-to-use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.

The company just released a shareholder letter; in it, there is a list of the company’s latest accomplishments. The list below is impressive and is a big reason why the company is starting a major rally.

Highlights include:

Signing two marketing agreements with well-established medical device sales organizations
Establishment and expansion of a rapidly growing sales department
The completion of the purchase price to the seller of the SofPulse Technology
The new Roma medical device is on schedule for release in Q1 of 2019

ENDV also just filed a patent infringement lawsuit today in the U.S. District Court for the Central District of California against KVP INTERNATIONAL, INC., a California Corporation, ORTHOCOR MEDICAL, INC., a Delaware Corporation, and CAERUS CORP., a Minnesota Corporation. The lawsuit states the aforementioned companies make, market, import, use, sell, and/or offer for sale several products and related services within the United States which infringe Endonovo’s Patents. This could add even more capital to the company’s bottom line.

Start your research on ENDV.

_______

Aphria, Inc. (NYSE: APHA) (Market Cap: $2.58B, Share Price: $10.42) announced that Health Canada has granted the company its license amendment, permitting Aphria to commence production in an additional 800,000 square feet of facilities at its Aphria One location, as part of the company's completed Part IV and Part V expansions.
_______

Another medical device company like ENDV, Avinger, Inc. (NASDAQ: AVGR) (Market Cap: $15.952M Share Price: $0.68), announced that it will release its financial results for the fourth quarter and full year 2018 after the close of trading on Wednesday, March 6, 2019.

_______

BioPharmX Corporation (BPMX) (Market Cap: $24.451M, Share Price: $0.1120) completed enrollment of its Phase 2b clinical trial with BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
_______

Valeritas Holdings, Inc. (NASDAQ: VLRX) (Market Cap: $50.675M, Share Price: $0.5070) announced that the Compensation Committee of Valeritas’ Board of Directors granted stock options to purchase an aggregate of 244,400 shares of Valeritas’ common stock to 31 newly-hired employees, with a grant date of February 27, 2019, pursuant to the Valeritas Holdings, Inc. 2018 Inducement Plan that was previously disclosed.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at any time by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Mar 2024 to Apr 2024